Tegavivint for advanced liver cancer after prior treatments
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests tegavivint in people with advanced hepatocellular carcinoma (HCC), a type of liver cancer. It’s meant for cases where the cancer can’t be treated with curative surgery/local procedures or has progressed after standard systemic medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have confirmed advanced HCC
- Your liver function is good enough for study medicine (Child-Pugh A, or B with score 7 or less), and you don’t have liver-related confusion
- Your cancer has measurable spots on CT or MRI that can be tracked over time
- You can have tumor biopsies (small tissue samples) during screening and while on treatment
- You have tried at least one standard systemic medicine for advanced HCC and either it didn’t work, you couldn’t tolerate it, or it was not safe for you
- Your blood counts and organ tests (kidneys, liver, and others) meet specific minimums
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This trial tests two new drugs together for people with advanced liver cancer that has not responded to other treatments or who cannot take standard immunotherapies. The combination aims to target specific genetic changes in the tumor to slow or stop its growth.
This trial tests a new drug (WGI-0301) combined with an existing liver cancer medicine (lenvatinib). It aims to see if the combination can help people with advanced liver cancer when other treatments haven't worked.
This study tests a new drug, cabozantinib, for people with liver cancer that has grown despite previous treatment with atezolizumab and bevacizumab. The goal is to see if this drug can help control the cancer.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.